Lupin shares hit 52-week high on strong Q2 results
The company's revenue from operations in the Q2 of FY24, stood at ₹5,038.6 crore, up 21.5% YoY as against ₹4,145.5 crore in the same period last year.
The company's revenue from operations in the Q2 of FY24, stood at ₹5,038.6 crore, up 21.5% YoY as against ₹4,145.5 crore in the same period last year.
The share price of the company surged as much as 4.08% to hit a 52-week high of ₹1,174.00 in early session.
The pharma major’s subsidiary has launched Propranolol LA capsules, 60 mg, 80 mg, 120 mg, and 160 mg, in Canada.
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.